Who is eligible for clinical trial NCT06830798?

Participants must meet the protocol's inclusion criteria for Delayed Graft Function. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06830798 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-17

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation (NCT06830798)

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Alexion Pharmaceuticals, Inc.

🩺 Plain-English Summary (8th-Grade Level)

The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (3 items).

Location: Research Site — Phoenix, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

≥ 18 years of age at the time of signing the informed consent
Diagnosed with Dialysis-dependent End-Stage Kidney Disease (ESKD)
A candidate for kidney transplant from:
Donation after Circulatory Death (DCD) donor
High-risk Donation after Brain Death (DBD) donor

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Is to receive a kidney from a donor with category I,II,IV and V Maastricht Classification
Diagnosed with Acute Kidney Injury (AKI) of Stage 3 severity according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (130 Sites)

Showing the first 25 of 130 sites.

Research Site — Phoenix, Arizona
Research Site — Los Angeles, California
Research Site — San Francisco, California
Research Site — San Francisco, California
Research Site — Stanford, California
Research Site — New Haven, Connecticut
Research Site — Jacksonville, Florida
Research Site — Tampa, Florida
Research Site — Atlanta, Georgia
Research Site — Chicago, Illinois
Research Site — Chicago, Illinois
Research Site — Fairway, Kansas
Research Site — Lexington, Kentucky
Research Site — Kenner, Louisiana
Research Site — Ann Arbor, Michigan
Research Site — Detroit, Michigan
Research Site — Minneapolis, Minnesota
Research Site — St Louis, Missouri
Research Site — Omaha, Nebraska
Research Site — Livingston, New Jersey
Research Site — New York, New York
Research Site — New York, New York
Research Site — Durham, North Carolina
Research Site — Philadelphia, Pennsylvania
Research Site — Greenville, South Carolina

📞 Contact the Study Coordinator

Phone: (855) 752-2356

Email: clinicaltrials@alexion.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Delayed Graft Function

The Impact of Intraoperative Diuretic Use on Delayed Graft Function Following Deceased Donor Renal Transplantation — London, Ontario
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function — Los Angeles, California

Explore by condition: All Delayed Graft Function clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗